Advocacy intelligence hub — real-time data for patient organizations
University of California, San Diego — PHASE1, PHASE2
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Barbara Nemesure — NA
Shanghai East Hospital
Dana-Farber Cancer Institute — NA
Jiangsu HengRui Medicine Co., Ltd. — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Leukine
(Sargramostim)Orphan drugstandardImmunex Corporation
Leukocyte Growth Factor [EPC]
12.1 Mechanism of Action Sargramostim (GM-CSF) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal e...
Blenoxane
(Bleomycin sulfate)Orphan drugstandardBristol-Myers Squibb Pharmaceutical Research Institute
Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the i...
Project Leader
Ono Pharmaceutical Co. Ltd
Tracy Batchelor, MD, MPH, MD MPH
Massachusetts General Hospital
📍 BOSTON, MA
Leona Holmberg
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Simran Singh
Sobi, Inc.
📍 Birmingham, Alabama
Eric Jacobsen, MD
Dana-Farber Cancer Institute
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH